Ticker

GSK plc (GSK) is making a calculated bet on next generation gene silencing drugs, signing a licensing agreement worth up to $1 billion with China's Frontier Bio

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 Type: Fireside Chat Presentation Date/Time: March 2, 2026, 11:50 a.m. EST Leerink 2026 Global Healthcare Conference – March 8-11, 2026 Type: Fireside Chat Presentation Date/Time:…

China Universal Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 52.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,234 shares of the biotechnology company's stock after acquiring an additional 14,497 shares during

Rhumbline Advisers increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 3.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 371,112 shares of the biotechnology company's stock after purchasing an additional 11,115 shares during the quarter.

AlphaQuest LLC lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 93.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,080 shares of the biotechnology company's stock after selling 30,501 shares during the quarter. AlphaQuest LLC's holdings